FY2026 Earnings Estimate for Myomo Issued By HC Wainwright

Myomo, Inc. (NYSEAMERICAN:MYO) – Stock analysts at HC Wainwright decreased their FY2026 earnings estimates for Myomo in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst S. Lee now anticipates that the company will earn $0.00 per share for the year, down from their prior estimate of $0.05. HC Wainwright currently has a “Buy” rating and a $9.50 target price on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo’s FY2028 earnings at $0.42 EPS and FY2029 earnings at $0.60 EPS.

Several other research analysts have also issued reports on MYO. Craig Hallum increased their price target on shares of Myomo from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, March 11th. Alliance Global Partners reissued a “buy” rating on shares of Myomo in a research report on Tuesday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $9.25.

Myomo Price Performance

Shares of MYO opened at $5.19 on Friday. The stock has a market cap of $157.00 million, a PE ratio of -22.57 and a beta of 1.68. Myomo has a 52 week low of $2.51 and a 52 week high of $7.17.

Insiders Place Their Bets

In other Myomo news, insider Micah Mitchell sold 48,000 shares of the company’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $5.16, for a total transaction of $247,680.00. Following the sale, the insider now directly owns 140,572 shares of the company’s stock, valued at approximately $725,351.52. This represents a 25.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas F. Kirk acquired 7,400 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were purchased at an average cost of $5.00 per share, for a total transaction of $37,000.00. Following the completion of the purchase, the director now directly owns 255,933 shares of the company’s stock, valued at approximately $1,279,665. The trade was a 2.98 % increase in their position. The disclosure for this purchase can be found here. Insiders own 4.54% of the company’s stock.

Institutional Trading of Myomo

Several hedge funds have recently modified their holdings of the stock. Northern Trust Corp grew its stake in shares of Myomo by 17.6% during the fourth quarter. Northern Trust Corp now owns 49,587 shares of the company’s stock valued at $319,000 after purchasing an additional 7,413 shares during the last quarter. Barclays PLC bought a new stake in shares of Myomo during the third quarter valued at approximately $36,000. BNP Paribas Financial Markets bought a new stake in shares of Myomo during the fourth quarter valued at approximately $64,000. Walleye Capital LLC bought a new stake in shares of Myomo during the fourth quarter valued at approximately $66,000. Finally, Squarepoint Ops LLC acquired a new position in Myomo in the fourth quarter valued at approximately $74,000. 44.99% of the stock is owned by institutional investors.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.